6 Analysts Have This to Say About Inozyme Pharma
Portfolio Pulse from Benzinga Insights
Inozyme Pharma (NASDAQ:INZY) has received predominantly bullish ratings from analysts in the last quarter, with 5 out of 6 analysts giving a bullish rating. The average 12-month price target for the stock is $19.33, an increase of 1.74% from the previous average price target of $19.00.
September 27, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma has received predominantly bullish ratings from analysts, indicating a positive outlook for the stock. The increased average price target suggests potential upside.
The bullish ratings from analysts indicate a positive sentiment towards Inozyme Pharma. The increase in the average price target suggests that analysts believe the stock has potential for growth, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100